Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection

Brandon Wilder, Stefan H.I. Kappe, D. Noah Sather

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: An effective malaria vaccine would be considered a milestone of modern medicine, yet has so far eluded research and development efforts. This can be attributed to the extreme complexity of the malaria parasites, presenting with a multi-stage life cycle, high genome complexity and the parasite’s sophisticated immune evasion measures, particularly antigenic variation during pathogenic blood stage infection. However, the pre-erythrocytic (PE) early infection forms of the parasite exhibit relatively invariant proteomes, and are attractive vaccine targets as they offer multiple points of immune system attack. Areas covered: We cover the current state of and roadblocks to the development of an effective, antibody-based PE vaccine, including current vaccine candidates, limited biological knowledge, genetic heterogeneity, parasite complexity, and suboptimal preclinical models as well as the power of early stage clinical models. Expert commentary: PE vaccines will need to elicit broad and durable immunity to prevent infection. This could be achievable if recent innovations in studying the parasites’ infection biology, rational vaccine selection and design as well as adjuvant formulation are combined in a synergistic and multipronged approach. Improved preclinical assays as well as the iterative testing of vaccine candidates in controlled human malaria infection trials will further accelerate this effort.

Original languageEnglish (US)
Pages (from-to)403-414
Number of pages12
JournalExpert Review of Vaccines
Volume16
Issue number5
DOIs
StatePublished - May 4 2017
Externally publishedYes

Fingerprint

Malaria
Vaccines
Antibodies
Infection
Parasitic Diseases
Parasites
Malaria Vaccines
Immune Evasion
Antigenic Variation
Modern 1601-history
Genetic Heterogeneity
Proteome
Life Cycle Stages
Immune System
Immunity
Genome
Research

Keywords

  • antibody
  • immunology
  • Malaria
  • plasmodium
  • pre-erythrocytic
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection. / Wilder, Brandon; Kappe, Stefan H.I.; Sather, D. Noah.

In: Expert Review of Vaccines, Vol. 16, No. 5, 04.05.2017, p. 403-414.

Research output: Contribution to journalArticle

Wilder, Brandon ; Kappe, Stefan H.I. ; Sather, D. Noah. / Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection. In: Expert Review of Vaccines. 2017 ; Vol. 16, No. 5. pp. 403-414.
@article{cb553c446db149fb8e6f81a0ed960538,
title = "Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection",
abstract = "Introduction: An effective malaria vaccine would be considered a milestone of modern medicine, yet has so far eluded research and development efforts. This can be attributed to the extreme complexity of the malaria parasites, presenting with a multi-stage life cycle, high genome complexity and the parasite’s sophisticated immune evasion measures, particularly antigenic variation during pathogenic blood stage infection. However, the pre-erythrocytic (PE) early infection forms of the parasite exhibit relatively invariant proteomes, and are attractive vaccine targets as they offer multiple points of immune system attack. Areas covered: We cover the current state of and roadblocks to the development of an effective, antibody-based PE vaccine, including current vaccine candidates, limited biological knowledge, genetic heterogeneity, parasite complexity, and suboptimal preclinical models as well as the power of early stage clinical models. Expert commentary: PE vaccines will need to elicit broad and durable immunity to prevent infection. This could be achievable if recent innovations in studying the parasites’ infection biology, rational vaccine selection and design as well as adjuvant formulation are combined in a synergistic and multipronged approach. Improved preclinical assays as well as the iterative testing of vaccine candidates in controlled human malaria infection trials will further accelerate this effort.",
keywords = "antibody, immunology, Malaria, plasmodium, pre-erythrocytic, vaccine",
author = "Brandon Wilder and Kappe, {Stefan H.I.} and Sather, {D. Noah}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14760584.2017.1295853",
language = "English (US)",
volume = "16",
pages = "403--414",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection

AU - Wilder, Brandon

AU - Kappe, Stefan H.I.

AU - Sather, D. Noah

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: An effective malaria vaccine would be considered a milestone of modern medicine, yet has so far eluded research and development efforts. This can be attributed to the extreme complexity of the malaria parasites, presenting with a multi-stage life cycle, high genome complexity and the parasite’s sophisticated immune evasion measures, particularly antigenic variation during pathogenic blood stage infection. However, the pre-erythrocytic (PE) early infection forms of the parasite exhibit relatively invariant proteomes, and are attractive vaccine targets as they offer multiple points of immune system attack. Areas covered: We cover the current state of and roadblocks to the development of an effective, antibody-based PE vaccine, including current vaccine candidates, limited biological knowledge, genetic heterogeneity, parasite complexity, and suboptimal preclinical models as well as the power of early stage clinical models. Expert commentary: PE vaccines will need to elicit broad and durable immunity to prevent infection. This could be achievable if recent innovations in studying the parasites’ infection biology, rational vaccine selection and design as well as adjuvant formulation are combined in a synergistic and multipronged approach. Improved preclinical assays as well as the iterative testing of vaccine candidates in controlled human malaria infection trials will further accelerate this effort.

AB - Introduction: An effective malaria vaccine would be considered a milestone of modern medicine, yet has so far eluded research and development efforts. This can be attributed to the extreme complexity of the malaria parasites, presenting with a multi-stage life cycle, high genome complexity and the parasite’s sophisticated immune evasion measures, particularly antigenic variation during pathogenic blood stage infection. However, the pre-erythrocytic (PE) early infection forms of the parasite exhibit relatively invariant proteomes, and are attractive vaccine targets as they offer multiple points of immune system attack. Areas covered: We cover the current state of and roadblocks to the development of an effective, antibody-based PE vaccine, including current vaccine candidates, limited biological knowledge, genetic heterogeneity, parasite complexity, and suboptimal preclinical models as well as the power of early stage clinical models. Expert commentary: PE vaccines will need to elicit broad and durable immunity to prevent infection. This could be achievable if recent innovations in studying the parasites’ infection biology, rational vaccine selection and design as well as adjuvant formulation are combined in a synergistic and multipronged approach. Improved preclinical assays as well as the iterative testing of vaccine candidates in controlled human malaria infection trials will further accelerate this effort.

KW - antibody

KW - immunology

KW - Malaria

KW - plasmodium

KW - pre-erythrocytic

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85014498523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014498523&partnerID=8YFLogxK

U2 - 10.1080/14760584.2017.1295853

DO - 10.1080/14760584.2017.1295853

M3 - Article

VL - 16

SP - 403

EP - 414

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 5

ER -